InsidersTradesSigma
Neogenomics INC Stock: price and management transactions · United States · SEC (Form 4)
Follow the Neogenomics INC stock price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Neogenomics INC has logged 170 reports. Market capitalisation: €2bn. The latest transaction was filed on 13 May 2026 (Levée d'options). Among the most active insiders: Olivo Alicia C. Every trade is free.
170
Insider Decl.
0
Thresholds
€1m
8 ops.
Buy Volume
€14m
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Neogenomics INC Buy (bullish), based on 9 analysts. Average price target: US$15.11.
63Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 21,279 of 25,577 companies
28.2
score / 100
Value27
Quality30
FCF yld-1.2%
Earn yld-5.7%
EV/EBITDA·
ROE-12%
Gross mgn43%
Net mgn-15%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 13 May 2026
Declarations170 total
3,944 shares0Common StockSEC:0001628280-26-034620
3,944 shares0Common StockSEC:0001628280-26-034620:0
937 shares0Common StockSEC:0001628280-26-030622:0
5,372 shares0Common StockSEC:0001628280-26-030622:1
1,309 shares0Common StockSEC:0001628280-26-030622:2
12,254 shares0Common StockSEC:0001077183-25-000132
12,254 shares0Common StockSEC:0001077183-25-000132:0
13,005 shares0Common StockSEC:0001077183-25-000105:0
6,503 shares0Common StockSEC:0001077183-25-000106:0
9,613 shares0Common StockSEC:0001077183-25-000104:0
7,000 shares@ US$8.139225.3% of flowCommon StockSEC:0001077183-25-000100:0
Ideal exit: 3 Feb 2026 (T+270)
4,000 shares@ US$7.7811100.0% of flowCommon StockSEC:0001077183-25-000098:0
Ideal exit: 1 Feb 2026 (T+270)
18,900 shares@ US$7.8793100.0% of flowCommon StockSEC:0001077183-25-000096:0
Ideal exit: 31 Jan 2026 (T+270)
10,000 shares@ US$7.63100.0% of flowCommon StockSEC:0001077183-25-000094:0
Ideal exit: 30 Jan 2026 (T+270)
5,969 shares0Common StockSEC:0001077183-25-000088:0
20,000 shares@ US$7.5052100.0% of flowCommon StockSEC:0001077183-25-000090:0
Ideal exit: 27 Jan 2026 (T+270)
937 shares0Common StockSEC:0001077183-25-000082:0
652 shares0Common StockSEC:0001077183-25-000081:0
8,443 shares0Common StockSEC:0001077183-25-000041:0
8,443 shares0Common StockSEC:0001077183-25-000042:0
8,443 shares0Common StockSEC:0001077183-25-000043:0
15,535 shares0Common StockSEC:0001077183-25-000040:0
57,413 shares0Common StockSEC:0001077183-25-000039:0
7,070 shares0Common StockSEC:0001077183-25-000002:0
25 of 170 declarations
About Neogenomics INC
NeoGenomics, Inc. is a U.S.-listed oncology diagnostics company traded on the NASDAQ in the United States. Headquartered in Fort Myers, Florida, the group is focused on cancer genetics testing, pathology support, and precision-medicine solutions for oncologists, pathologists, hospitals, academic centers, and pharmaceutical partners. Its business model combines laboratory testing, advanced molecular diagnostics, and consultative services, making it one of the more specialized names in the oncology diagnostics space. Founded in the early 2000s, NeoGenomics has evolved from a regional laboratory operator into a broader oncology diagnostics platform with a nationwide footprint. In 2024, management simplified the operating structure into a single integrated segment, bringing Clinical Services and Advanced Diagnostics together. That move reflects a clearer commercial strategy and a stronger focus on operating efficiency, cross-selling, and end-to-end cancer testing workflows. The company’s menu includes cytogenetics, histopathology, molecular diagnostics, next-generation sequencing (NGS), biomarker testing, and therapy-selection tools designed to support diagnosis, treatment planning, and disease monitoring. From a competitive standpoint, NeoGenomics operates in a market that is both attractive and highly contested. It competes with large reference laboratories, molecular diagnostics companies, and specialized oncology testing providers. Its competitive edge lies in deep oncology specialization, a broad and clinically relevant test portfolio, medical interpretation capabilities, and a data-driven approach to precision medicine. The company is also notable for its geographic reach: it operates CAP-accredited and CLIA-certified laboratories across several U.S. locations, with an additional laboratory presence in Cambridge, United Kingdom. That footprint supports national service coverage and gives the company flexibility in sample processing and clinical support. Recent developments underscore NeoGenomics’ push toward higher-value, innovation-led growth. In the first quarter of 2026, the company reported 11% year-over-year revenue growth, led by 14% growth in Clinical revenue, and raised its full-year 2026 revenue guidance. Management also highlighted the launch of RaDaR ST, a ctDNA assay for molecular residual disease detection, along with a favorable MolDX coverage decision for PanTracer LBx and the introduction of PanTracer Pro. These initiatives strengthen the company’s oncology precision-testing platform and expand its addressable market in advanced cancer diagnostics. For investors, NeoGenomics is a U.S. NASDAQ-listed healthcare diagnostics company with a focused oncology franchise, improving operating momentum, and a product pipeline aimed at capturing secular growth in molecular testing and precision oncology.
